联合利妥昔单抗的人源化抗程序性死亡分子1单抗治疗复发滤泡性淋巴瘤的Ⅱ期临床试验:第54届美国血液学会年
会深度报道
褚福亮;Neelapu SS;杨林;Westin JR;张明;靖彧;李亚芬;汤金乐;宗云辉;刘彬;Davis RE
【期刊名称】《白血病·淋巴瘤》 【年(卷),期】2013(022)002
【摘要】Objective A phase Ⅱ trial of anti-programmed death-1 (PD-1) monoclonal antibody CT-011,an anti PD-1 humanized monoclonal antibody combined with rituximab therapy in patients with relapsed follicular lymphoma (FL) were conducted.Methods In order to evaluate the safety and efficacy of CT-011,the impacts of CT-011 on immune cells both from the peripheral blood (PB) samples and tumor microenvironment were examined.PB and core needle biopsies from involved lymph nodes were collected prior to and on day 14 after the first infusion of CT-011.PB mononuclear cells (PBMC) were analyzed by multiparametric flow cytometry to determine various immune cell subsets.Whole genome gene expression profiling (GEP) was performed on core needle biopsies.Results A significant increase in the absolute number of PB immune cells were observed in day 14 samples compared with baseline including total lymphocyte count (P ＜ 0.01),CD+3 T cells (P =0.01),CD+4 T cells (P ＜ 0.01).Comparison of GEP from core needle biopsies obtained pretreatment and day 14 (n =8 pairs) showed up
联合利妥昔单抗的人源化抗程序性死亡分子1单抗治疗复发滤泡性淋
